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Abstract: Glioblastoma is one of the most common primary brain tumors and one of the most 
difficult to treat. In population-based studies only 30% of patients will survive 1 year and in the 
most efficacious surgery, irradiation, and chemotherapy clinical trials approximately 20% will 
live 2 years. Bevacizumab is a recombinant, antivascular epidermal growth factor receptor 
(VEGF) monoclonal antibody with 6 VEGF-binding residues that binds to VEGF, preventing 
VEGF from binding to its target, VEGFR-1 and VEGFR-2, on endothelial cells. Through its 
binding to VEGF ligands bevacizumab reduces tumor angiogenesis and vasogenic brain edema; 
the consequences are that bevacizumab reduces the rate of glioblastoma tumor growth and its 
associated tumoral edema, thereby improving quality of life and survival for patients suffering 
from cerebral glioblastoma. In this review, we will summarize the studies that led to the use of 
bevacizumab in glioblastoma and the potential side-effects and complications that can be associ-
ated with its use and, finally, new opportunities for drug combinations with bevacizumab.
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Introduction
Glioblastoma multiforme (GBM) is a primary brain tumor arising from cells of 
astrocytic lineage. GBM is one of the most common and aggressive malignancies 
of the central nervous system (CNS). Despite its aggressiveness, there are molecular 
differences among all glioblastomas that result in a range of responsiveness to treat-
ment. Primary glioblastomas arise without a preceding low grade glioma, often show 
amplification of epidermal growth factor receptor (EGFR) and murine double minute 
2 (MDM2), along with inactivation of phosphatase and tensin homolog (PTEN) and 
p16 tumor suppressor genes. Secondary glioblastomas often have loss of p53 and 
pRB, as well as an increase in CDK4/6 expression. In 2005, Hegi and colleagues were 
able to show that outcome for patients with newly diagnosed glioblastomas depended 
on the methylation status of O6-methylguanine DNA methyltransferase (MGMT), 
with median survival increasing to 21.7 months in those with methylation of MGMT 
treated with both external beam irradiation and temozolomide.1 As a result, molecular 
profiling of glioblastoma tissue collected at surgery is becoming important to patient 
treatment considerations and care.
The incidence rate of GBM is 3.1 per 100,000 person-years,2 overall incidence 
of gliomas is greater in males (7.2 per 100,000 person-years) compared to females 
(5.0 per 100,000 person-years) and increases with age to 14/100,000 over age 65. The 
incidence rate is also greater amongst Caucasians compared to other ethnicities, and 
18.5% of all brain tumors are GBM.2Cancer Management and Research 2010:2 98
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The median age at diagnosis of GBM is 64 years, and 
GBM is the second most common primary brain tumor 
behind only meningioma in patients at least 45 years of age.2 
Based on general tumor registry data, approximately 29.6% 
of patients with GBM will survival 1 year, whereas only 
3.4% will survive 5 years with treatment.2
Studies evaluating risk factors for brain tumors have 
thus far shown previous exposure to ionizing radiation 
as a statistically significant risk factor, but no conclusive 
evidence yet supports electromagnetic fields, cell phones, 
neurocarcinogens or metals as increasing risk of brain tumor 
development.3 There are specific genetic disorders that are 
associated with an increased risk for developing malignan-
cies, including brain tumors, and these include Li-Fraumeni 
syndrome, Neurofibromatosis, Tuberous Sclerosis, von 
  Hippel-Lindau syndrome, and Turcot syndrome, but only 
5% to 10% of brain tumors are inherited.4
Vascular endothelial growth factor 
(VEGF) pathways and high-grade 
gliomas
VEGF is a potent endothelial cell mitogen and key regulator 
of both physiologic vasculogenesis in the embryonic circu-
latory system5 and pathologic angiogenesis leading to the 
growth of blood vessels from existing vasculature.6,7 VEGF 
has also been shown to stimulate monocyte/macrophage 
migration,8–10 stimulate tumor cell migration,11–15 and enhance 
vascular permeability in tight-junction endothelial environ-
ments such as those of the intact blood-brain barrier.16–18
There are five known subtypes of VEGF (VEGF-A, 
-B, -C, -D and -E) and three known VEGF receptors 
(VEGFR-1, -2 and -3), all of which are tyrosine kinases.19 
VEGF A, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) are 
all highly expressed in the CNS. For CNS tumors, VEGF-A 
appears to bind to VEGFR-1 and VEGFR-2 and serve a 
particularly critical role for both angiogenesis and regulation 
of vascular permeability of the blood – brain barrier.6,16–18 
VEGF-A stimulates endothelial proliferation via binding 
to VEGFR-2, and VEGFR-1 is involved in recruitment of 
macrophages/monocytes that in turn secrete pro-angiogenic 
factors. VEGF-A is known to stimulate vascular leakage, in 
particular through VEGFR-1 and VEGFR-2,19 and this may 
contribute to the destabilization (increasing leakiness) of the 
blood – brain barrier that is often seen in malignant gliomas. 
Malignant gliomas as well as many other cancers are known 
to secrete VEGF as a means to stimulate the development 
of tumor vascular supply (angiogenesis). In turn, expression 
of VEGF appears to be upregulated by hypoxia as well as 
a variety of signal and transcription factors.19 Specifically 
upregulated by hypoxia are:
1.  HIF-1α20,21
2.  STAT322,23
3.  Src20,24
4.  EGFR pathway25,26
5.  FoxM1B transcription factor27
6.  Hurl suppresses degradation of VEGF-A mRNA28,29
While it is important to identify increased expression of 
VEGF-A, VEGFR-1 and VEGFR-2 in malignant gliomas, 
correlation to tumor growth is instrumental as well. Kerber 
and colleagues studied mice with transplanted glioma cells 
and mice transplanted with either wild-type bone marrow 
cells or with VEGFR-1 lacking a tyrosine kinase domain.30 
They found, using an original glioma cell line and a VEGF-A 
overexpressing cell line, that a significant reduction in growth 
of tumor was observed in those mice lacking wild-type 
VEGFR-1. Studies such as this suggest that VEGF-A 
and VEGFR-1 may be critical pathways in the growth of 
  malignant gliomas.
Preclinical pharmacology studies
Bevacizumab is a recombinant, anti-VEGF monoclo-
nal antibody with 6 VEGF-binding residues that binds 
to VEGF, preventing VEGF from binding to its target, 
VEGFR-1 and VEGFR-2, on endothelial cells.31 Bao and 
colleagues examined stem cell-like glioma cells (SCLGC) 
to determine if such cells may be involved in angiogenesis 
and tumor development.32 SCLGC were isolated from 
human glioblastoma tissue and implanted intracranially into 
mice. SCLGC, when compared to matched non-SCLGC 
controls, exhibited higher concentrations of VEGF, and 
hypoxia seemed to induce VEGF expression. Bevacizumab 
eliminated angiogenesis and suppressed growth of SCLGC, 
when compared to matched non-SCLGC controls. The 
authors concluded that stem-cell like tumors cells could 
contribute to angiogenesis in certain forms of cancer, such 
as gliomas.
Preclinical evaluation of antiangiogenic protein 
expression in four glioma cell lines after treatment with 
  temozolomide found that levels of HIF-1a, ID-1, ID-2 and 
c-Myc were all reduced. Since these four factors are believed 
to be involved in angiogenesis and hypoxic metabolism, 
it was hypothesized that by reducing the levels of these 
factors, temozolomide may contribute to the reduction of 
angiogenesis in glioma. The authors also found that, when 
bevacizumab was added to temozolomide, the survival of Cancer Management and Research 2010:2 99
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mice with glioma improved, compared to mice treated with 
either compound alone.33
To test the hypothesis that inhibition of hypoxia inducible 
factor-1 (HIF-1), when given with antiangiogenic agents, 
might be more efficacious, bevacizumab was given alone 
or with topotecan, a topoisomerase inhibitor, with HIF-1α 
inhibitor activity.34 Using U251-HRE xenografts, the authors 
showed that bevacizumab reduced microvessel density and 
increased hypoxia and expression of the HIF-1 dependent 
gene in the tumor, but it did not induce apoptosis. The 
addition of topotecan to bevacizumab significantly reduced 
tumor growth, compared to mice treated with topotecan or 
bevacizumab alone. Topotecan also reduced expression of 
HIF-1 and inhibited proliferation while inducing apoptosis. 
Since the cytotoxic benefit of topotecan did not change with 
the addition of bevacizumab, the authors concluded that 
topotecan exerted its effect by HIF-1 inhibition. Furthermore, 
they hypothesized that bevacizumab, functioning as an anti-
angiogenesis agent, may represent a potentially beneficial 
two-drug treatment strategy.34
Clinical phase II studies  
at tumor recurrence
It is apparent from preclinical studies that VEGF is impor-
tant for growth of endothelial cells and regulation of tumor 
angiogenesis; treatment with bevacizumab in vascular tumors 
like malignant gliomas was anticipated for many years 
prior to the initiation of formal clinical studies. Nonethe-
less, the first documented usage of bevacizumab in patients 
with glioblastoma was in an uncontrolled clinical trial by 
Stark-Vance in 2005. She presented a series of 29 patients, 
all with recurrent malignant glioma, treated with bevaci-
zumab in combination with irinotecan.35 Stark-Vance used 
bevacizumab 5 mg/kg and irinotecan 125 mg/m2 together, 
intravenously, every 2 weeks, with a 1- to 2-week break 
between each cycle. There were 3 complete responses (CR), 
16 partial responses (PR) and 7 stable diseases (SD); thus, at 
least 65% of patients in this case series achieved a response 
to treatment. Toxicities attributed to bevacizumab included 
1 intracranial hemorrhage, 1 bowel perforation, 2 wound-
healing abnormalities and 5 cases of epistaxis.35
The schedule of most phase 2 studies was based on an 
intravenous treatment with bevacizumab on a once every 14-
day schedule. This was established by Genentech based on the 
plasma clearance half-life of approximately 21 days. While 
toxicity secondary to bevacizumat is generally mild, neverthe-
less, since bevacizumab may interfere with wound healing, it 
is recommended today to wait a minimum of 28 days before 
or after a major surgical procedure to administer bevacizumab 
to lower the risk of adverse events such as wound hemor-
rhage and breakdown. Bevacizumab was approved by the US 
Food and Drug Administration for recurrent glioblastoma in 
May 2009. Below we will chronicle some of the studies that 
led to that approval.
In an early phase II trial, 9 patients with malignant glioma 
and 23 with glioblastoma were treated with a combination of 
bevacizumab and irinotecan (Table 1).36 Specifically, these 
patients were treated with bevacizumab 10 mg/kg IV every 
2 weeks and irinotecan 125 mg/m2 for patients on enzyme-
inducing antiepileptic medication (EIAED) or 340 mg/m2 
for patients not on EIAED. Twenty patients (63%) achieved a 
radiographic response to treatment. Of the 23 glioblastomas, 
14 patients (61%) achieved a partial response or better, with 
a median progression-free survival (PFS) of 20%. Three 
patients developed deep venous thromboses or pulmonary 
emboli, and 1 patient had a stroke. There were no cases of 
intracranial hemorrhages.36
In another retrospective analysis of bevacizumab com-
bined with cytotoxic chemotherapy (irinotecan, carboplatin, 
carboplatin with erlotinib, carmustine or temozolomide) 
for recurrent malignant gliomas, a total of 55 patients were 
reviewed and 63% showed a response to treatment and 
30% had stable disease (Table 1).37 The results of this trial 
included a 6-month PFS of 42% for glioblastoma and 32% 
for anaplastic glioma. Twenty-three patients, at progres-
sion, continued bevacizumab but changed chemotherapeutic 
Table 1 Compilation of phase II studies using bevacizumab for recurrent glioblastoma
Patients  Treatment  Radiographic response  
(MR, PR, CR)
PFS 
at 6 months
Overall survival 
23 BEV + irinotecan36 61% 30% Median 9 mos
33 BEV + CT37 64% 42% N/A
48 BEV38 71% 29% Median 7 mos
85  
82
BEV41  
BEV + irinotecan41
28%  
38%
43%  
50%
Median 9 mos  
Median 9 mos
Abbreviations: PFS, progression-free survival; MR, minor response; PR, partial response; CR, complete response; BEV, bevacizumab; CT, variable cytotoxic chemotherapy.Cancer Management and Research 2010:2 100
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agents, and this resulted in no radiographic responses, but 
2 patients had prolonged PFS. The authors also noted a 
  pattern of increased volume of infiltrative, nonenhancing 
tumor in those patients who progressed while on bevaci-
zumab. The conclusion reached was that, while bevacizumab 
combined with cytotoxic chemotherapy is active in patients 
with malignant gliomas, changing chemotherapeutic agents 
at progression proved beneficial in only a small subset of 
patients and progression of tumor seemed to occur in a non-
enhancing, infiltrative pattern.37
In another phase II trial of patients with recurrent glioblas-
toma, 48 patients with recurrent glioblastoma were treated 
with bevacizumab 10 mg/kg every 2 weeks until tumor 
progression, then irinotecan was added to bevacizumab, 
either 340 mg/m2 or 125 mg/m2, depending on EIAED status 
(Table 1).38 While on bevacizumab alone, 34 patients (71%) 
achieved a radiographic response based on Levin criteria,39 
compared to 17 patients (35%) when using Macdonald 
criteria.40 The 6-month PFS was 29%, and 6-month overall 
survival (OS) was 57%. 19 patients were treated with beva-
cizumab and irinotecan at progression, and no radiographic 
responses were observed.
In a larger multi-institutional phase II trial of bevacizumab 
alone or in combination with irinotecan for recurrent glioblas-
toma, 167 patients were randomly assigned to bevacizumab 
10 mg/kg every 2 weeks alone or with irinotecan 340 mg/m2 or 
125 mg/m2, depending on EIAED status (Table 1).41 For those 
patients on bevacizumab alone, 6-month PFS was 43%, objec-
tive response rates were 28% and median OS was 9 months. For 
those patients on bevacizumab and irinotecan, 6-month PFS 
was 50%, objective response rates were 38%, and median OS 
was 8.7 months. The bevacizumab-alone group experienced 
grade 3 or higher adverse events, including hypertension (8%) 
and seizures (6%). The bevacizumab and irinotecan group also 
experienced grade 3 or higher adverse events, including sei-
zures (14%), neutropenia (9%) and fatigue (9%). Two patients 
in the bevacizumab-alone group had a grade 1 intracranial 
hemorrhage (2%), compared to 3 patients (4%) in the bevaci-
zumab and irinotecan-group (grade 1, 2 and 4).41
It is difficult to make a straightforward comparison of 
bevacizumab to cytotoxic agents used to treat GBM because 
of the unusual action of bevacizumab and the fact that it does 
not directly damage DNA of dividing tumor cells. In addi-
tion, bevacizumab reduces cerebral edema through a direct 
effect on brain capillary endothelial cells thus leading to a 
high “response rate”. On the other hand, alkylating agents 
only secondarily reduce peritumoral edema when they reduce 
tumor and neoplastic endothelial cell burden. Furthermore, 
for PFS, comparing bevacizumab and cytotoxic agents can 
also be misleading, especially since they are not mutually 
exclusive therapies but rather may be complementary. Lastly, 
much of the early single-agent cytotoxic chemotherapy 
literature occurred before the current magnetic resonance 
imaging (MRI) era became widespread. Nonetheless, for 
interest’s sake we will cite some conclusions from the cyto-
toxic literature for recurrent GBM.
For this purpose, we selected BCNU,42–44 procarbazine,45,46 
carboplatin,47 and temozolomide46 data that were analyzed 
for a prior review.48 Since response to these therapies is 
under 50% the median will generally be about 8 weeks for 
all studies. Therefore, in order to better understand and com-
pare alkylating agent therapy to bevacizumab, we elected to 
combine response and stable disease patients in order to look 
at duration of therapy benefit. As summarized in table 2, those 
studies show combined response (PR, CR) and stable disease 
(minor response [MR], SD) rates of 27% to 46% with median 
time to progression (MTP) of 22 to 30 weeks.48 Thus, even 
though the metrics used in Tables 1 and 2 are different (PFS 
at 6 months vs. MTP) and the response criteria differ between 
the study groups (MR + PR + CR vs. SD + MR + PR + CR) 
summarized in the two tables, one can appreciate that beva-
cizumab therapy benefits more patients than the cytotoxic 
drugs, and the durability of a benefit appears to be some-
what longer. That bevacizumab can be combined with some 
cytotoxic drugs without increasing myelotoxicity should be 
viewed as encouraging.
Clinical phase II studies  
and translational research
A retrospective review of 44 patients treated with beva-
cizumab for recurrent glioblastoma were compared to 
79 patients who were not treated with bevacizumab.49 The 
authors found a significant improvement in PFS and OS in 
the group treated with bevacizumab. In addition, patients age 
55 years or older and those with a Karnofsky Performance 
Table 2 Compilation of selected phase II studies of cytotoxic drugs 
for treatment of recurrent glioblastoma
Treatment  Radiographic response  
(SD, MR, PR, CR)
MTPa 
BCNU42–44 29 22
Procarbazine45,46 27–33 30
Carboplatin47 40 20
Temozolomide46 46 20
aMTP, median time to tumor progression for the SD and responding patients.Cancer Management and Research 2010:2 101
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Status of 80 or less had an improved PFS when treated with 
bevacizumab. VEGF expression in glioblastoma specimens 
collected on all patients, analyzed with DNA microarray 
analysis, was higher in patients at least 55 years of age. Lastly, 
those patients treated with bevacizumab required a lower 
dose of dexamethasone, and retained their level of function 
longer when treated with bevacizumab.49
Sathornsumetee and colleagues conducted a phase II trial, 
searching for biomarkers that could predict outcome and 
response to treatment in patients with recurrent malignant 
astrocytomas.50 Tumor tissue was collected from 27 patients 
with GBM and 18 with anaplastic astrocytoma at initial diag-
nosis. The tissue was studied using immunohistochemistry to 
semi-quantitate expression of VEGF, VEGF receptor 2, CD31, 
hypoxia-inducible carbonic anhydrase 9 (CA9), and HIF-2α. A 
total of 58% experienced PR or more. Elevated expression of 
VEGF was associated with a greater likelihood of response to 
treatment, but not a survival benefit. Elevated CA9 expression 
was associated with a poor outcome, and thus hypoxia, not 
angiogenesis, ultimately determined survival in this patient 
population. Median survival for patients with elevated CA9 
expression was 37 weeks, while those with low CA9 expression 
was 74 weeks. The best prognosis was associated with patients 
whose tumor tissue was negative for CA9 and HIF-2α, whereas 
those who expressed both CA9 and HIF-2α had the worst 
prognosis. There were no significant differences in survival 
for angiogenic markers VEGF, VEGFR-2 or CD31.50
Lucio-Eterovic and colleagues compared U87 glioblas-
toma cell lines and NSC23 glioma stem cell lines with respect 
to the effects of bevacizumab on in vitro and in vivo invasion, 
and sought to identify potential mechanisms of resistance 
to treatment.14 These authors were able to show that both 
cell lines treated with bevacizumab were able to upregulate 
expression of molecules important for angiogenesis, such 
as fibroblastic growth factors, interleukins and angiogenins, 
thereby bypassing the antiangiogenic effect of bevacizumab. 
Furthermore, there were increased levels of invasion-related 
proteins (MMP-2, MMP-9, MMP-12, SPARC and TIMPs), 
suggesting both cell lines treated with bevacizumab may use 
this as a mechanism for increasing tumor invasiveness.14
Clinical phase II studies  
with irradiation
A phase II pilot study of bevacizumab in combination with 
temozolomide and radiation therapy was reported for patients 
with newly diagnosed glioblastoma multiforme.51 In this 
study, all patients were treated with standard external beam 
irradiation (60 Gy in 30 fractions, 3 to 5 weeks followed 
surgery), concurrent temozolomide (75 mg/m2 for 42 days 
during radiation therapy), and bevacizumab 10 mg/kg every 
2 weeks, starting on day 1 of radiation therapy (RT). After RT 
was completed, adjuvant temozolomide chemotherapy was 
continued at 150 to 200 mg/m2, days 1 to 5 every 28 days, 
and bevacizumab was continued at 10 mg/kg every 2 weeks. 
Though preliminary data analysis was encouraging, the 
  routine use of this regimen was not advocated pending 
completion of a larger, ongoing phase II trial.51
Gutin and colleagues studied the safety and efficacy of 
bevacizumab in patients with recurrent malignant gliomas 
who also received stereotactic radiation therapy.52 25 patients 
with recurrent malignant glioma, who already received 
standard radiation therapy, were treated with bevacizumab 
10 mg/kg every 2 weeks until tumor recurrence. These 
patients were also treated with 30 Gy of stereotactic radiation 
therapy in 5 fractions after the first course of bevacizumab. 
Three patients discontinued bevacizumab due to grade 
3 intratumoral hemorrhage, wound dehiscence, and/or bowel 
perforation. No radiation necrosis was seen in any patients. 
In patients with GBM, the response rate was 50%, with a 
6-month PFS of 65%, and a median OS of 12.5 months.52
Clinical trials with anticoagulation
A retrospective review evaluated the safety of using anti-
coagulation in glioma patients who were also treated with 
bevacizumab.53 In this report, 21 patients were treated with 
anticoagulation and bevacizumab for a median of 72 days. 
No large lobar hemorrhages were noted, although 14% (3/21) 
patients had small areas of hemorrhage and only 5% (1/21) 
developed symptoms from the small hemorrhage. No patients 
sustained permanent neurological impairments. Interestingly, 
7 patients were also identified who developed symptomatic 
hemorrhages while on bevacizumab but were not receiving 
anticoagulation. The authors concluded that anticoagulation 
is not a contraindication to starting bevacizumab.53
Bevacizumab and neuroimaging
A retrospective analysis of patterns of relapse and prog-
nosis, once tumor progression has occurred, was reported 
for 37 patients with recurrent GBM on bevacizumab.54 The 
median OS after tumor progression on bevacizumab was 
4.5 months, with a pattern of progression characterized by an 
increase in enhancement at the original site of tumor (46%), 
a new enhancing lesion distant to the original tumor location 
(16%), and growth of nonenhancing tumor (35%). Additional 
chemotherapy was given to those with tumor progression 
on bevacizumab, and the median PFS for these patients was Cancer Management and Research 2010:2 102
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2 months, with a median OS of 5.2 months and a 6-month 
PFS of 0%. The authors concluded that contrast MRI is not 
sufficient to fully assess treatment response of bevacizumab 
for recurrent GBM patients, especially since nonenhancing 
(T2 FLAIR) growth of tumor can be associated with a worse 
prognosis; additional chemotherapy following failure of 
bevacizumab provided only transient tumor control.54
In another retrospective analysis, 27 patients with recur-
rent high-grade glioma were treated with irinotecan and 
bevacizumab and evaluated for safety and efficacy.55 In this 
report, patients were treated with bevacizumab at 10 mg/kg 
every 2 weeks and irinotecan every 2 weeks (125 mg/m2 for 
those not on EIAEDs, 340 mg/m2 for those on EIAEDs). 
Six-month PFS was 46%, and median OS 13 months. Median 
number of prior therapies was 2 in this patient population. 
Interestingly, 12 patients had radiographic evidence for 
intracranial hemorrhage prior to receiving bevacizumab, yet 
only 1 patient required discontinuation of bevacizumab due 
to progression of hemorrhage. It was concluded that stable 
intracranial hemorrhage is probably not a contraindication 
to treatment with bevacizumab and irinotecan.55
Another retrospective analysis of 51 patients with recur-
rent high-grade gliomas treated with bevacizumab and 
  irinotecan was reported.56 In this series, patients were treated 
with bevacizumab 10 mg/kg and irinotecan (125 mg/m2 for 
those not on EIAEDs, 340 mg/m2 for those on EIAEDs) IV 
every 2 weeks. The 6-month PFS for anaplastic glioma was 
79% and 64% for glioblastoma. Of the 38 patients who expe-
rienced progression of disease, 23 showed distant progression, 
and 7 showed progression only on T2 FLAIR sequences. 
Twelve percent discontinued bevacizumab and irinotecan due 
to adverse events, including one with renal failure and another 
with gastric perforation. No intracranial hemorrhages were 
reported. The authors concluded that the high rate of distant 
progression may indicate an ability of the tumor to adapt to 
bevacizumab with a mechanism of infiltration.56
In a retrospective review of MRI from patients with GBM 
who reviewed bevacizumab-containing regimens, and evalu-
ated for the time course for imaging changes, 15 patients 
were identified who responded to a bevacizumab regimen and 
were available for MRI follow up for at least 7 months. The 
median time to best tumor response was 158 days (range, 16 
to 261), and the median best response was a 72% reduction 
in tumor volume and vasogenic edema.57
Bevacizumab and radiation necrosis
Bevacizumab appears to be active not only in the treat-
ment of patients with glioblastomas, but for those with 
  treatment-related changes from radiation therapy. The first 
paper to comment on this association was published in 2007.58 
Eight patients with malignant brain tumors (4 glioblasto-
mas, 3 anaplastic gliomas and 1 hemangiopericytoma) were 
classified as having radiation necrosis using MRI criteria,59 
although radiation necrosis was confirmed in 2 patients by 
biopsy. Following treatment with bevacizumab, alone or in 
combination with other chemotherapy agents, there was an 
average reduction of MRI enhancement of 48% and FLAIR 
size of 60%. Furthermore, there was a reduction in the aver-
age dexamethasone dose of 8 mg.
Another retrospective review of 6 patients (3 glioblas-
toma, 1 anaplastic astrocytoma, 1 anaplastic ependymoma 
and 1 astrocytoma), all with biopsy-proven radiation necro-
sis, were treated with bevacizumab. The average reduction 
in enhancement seen on MRI scans was 79%, and FLAIR 
images on MRI had an average signal reduction of 49%. The 
radiographic response rate reached 100%, and a response was 
maintained for a mean of 5.9 months (6 weeks to 18 months). 
The average number of bevacizumab infusions given was 6.8, 
and all patients were able to taper off dexamethasone.60
One of the authors (VAL) has completed a randomized, 
double-blind, placebo-controlled trial of bevacizumab in non-
GBM patients with radiation necrosis.61 This study strongly 
confirms the retrospective studies of bevacizumab effective-
ness in treating radiation necrosis of the CNS. It appears 
clear that bevacizumab can reduce capillary leakage, in a 
VEGF-dependent process, and thereby effectively manage 
vasogenic edema in patients with malignant brain tumors 
and radiation necrosis.30 In addition, reduction of VEGF by 
bevacizumab appears to stop the progression of radiation 
necrosis in many cases. Cliniclas must be cognizant of the 
possibility that this may confound our ability to truly evaluate 
response when using neuroimaging criteria in patients with 
glioblastoma who have MRI scans that could represent tumor 
progression and/or radiation necrosis.
Concluding remarks
Bevacizumab has thus far been shown to be active in patients 
with glioblastoma, with acceptable toxicity. Most serious 
adverse events, defined as grade 3 or 4 based on Common 
Terminology Criteria for Adverse Events (CTCAE) v3.0, 
are 5% or less, with exception to hypertension (range 6% to 
16%).62 Bevacizumab has been shown to improve survival, 
both PFS and OS, compared to historical controls in glioblas-
toma patients, with the most impressive response rates thus 
far for any such therapy. There are data to support activity of 
bevacizumab alone in patients with recurrent glioblastoma.Cancer Management and Research 2010:2 103
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The conundrum facing clinicians who use or would like 
to use bevacizumab to treat glioblastoma and anaplastic 
gliomas is how to best utilize its unique pharmacological 
actions on brain capillary permeability and its ability to 
interfere with tumor vessel formation. It is naïve to expect 
that bevacizumab combination with alkylating agents will 
achieve substantially more in terms of durable response since 
there is no unique interaction to be exploited. To date, most 
trials appear to be combinations of bevacizumab with DNA-
damaging agents and/or irradiation. Emerging data to show 
benefit with bevacizumab used at diagnosis along with temo-
zolomide have been judged encouraging based primarily on 
acceptable toxicity profiles when combining bevacizumab 
with standard conventional external beam irradiation or 
hypofractionated radiation therapy at recurrence. There are 
presently, however, a lack of randomized-controlled trials 
to provide definitive answers on the true impact of bevaci-
zumab-containing regimens for patients with glioblastoma. 
Trials such as RTOG 0825, which is presently open and 
evaluating newly diagnosed glioblastoma patients treated 
with standard external beam irradiation plus temozolomide 
versus standard external beam irradiation, temozolomide 
and bevacizumab, will address some of these concerns, 
although it may also point out the propensity of bevacizumab 
to alter glioma tumors to a more invasive phenotype.54
It is hoped that the continued identification of biomarkers 
and genetic patterns will identify patients who may benefit 
from anti-angiogenic agents such as bevacizumab, and these 
studies may also suggest other treatable cellular targets 
that may be critical to the advancement of treatment for 
glioblastoma patients. Lastly, given important issues of cost 
and toxicity, future randomized-controlled trials identifying 
optimal dose and length of treatment would be very helpful in 
optimizing use of bevacizumab for glioblastoma patients.
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